OncoCyte Corporation (OCX) Tops Q3 EPS by 32c

OncoCyte Corporation (NASDAQ: OCX) reported Q3 EPS of ($0.81), $0.32 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $430 thousand versus the consensus estimate of $437.5 thousand.

For earnings history and earnings-related data on OncoCyte Corporation (OCX) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge